Clinical Scorecard: Viral, Fungal Infections Drive Nonresolving ARDS

At a Glance

Key Highlights

• Invasive pulmonary aspergillosis (IAPA and CAPA) occurs in ~20% of ICU patients with severe viral pneumonia and doubles mortality risk.
• CMV and HSV can reactivate in ICU patients due to factors like mechanical ventilation, sepsis, and corticosteroid use, complicating ARDS.
• Diagnostic challenges include distinguishing colonization from invasive disease and lack of gold standards for viral reactivation significance.

Guideline-Based Recommendations

Diagnosis

• Use bronchoalveolar lavage (BAL) sampling with culture, galactomannan, and PCR for diagnosing invasive pulmonary aspergillosis.
• Recognize that serum galactomannan has limited sensitivity in non-neutropenic patients.
• Consider BAL over blood testing for detecting pulmonary CMV reactivation due to better reflection of lung infection.
• Acknowledge difficulty in defining clinically significant viral reactivation; detection of viral DNA does not confirm active infection.

Management

• Treat fungal superinfections with mold-active azoles (voriconazole, isavuconazole, posaconazole) as first-line therapy; liposomal amphotericin B as alternative.
• No definitive evidence supports routine antiviral treatment for HSV or CMV reactivation; preemptive acyclovir showed no ventilator-free day benefit in HSV.
• Systematic assessment of viral reactivation may be warranted given limited alternative treatable causes.

Monitoring & Follow-up

• Frequent respiratory sampling (e.g., BAL) in ICU patients with nonresolving ARDS to detect fungal and viral infections.
• Monitor timing differences in aspergillosis onset: early (within 48 hours) in influenza-associated cases, later (~1 week) in COVID-19-associated cases.

Risks

• High mortality (~50%) associated with Aspergillus superinfection in viral ARDS.
• Corticosteroid therapy and prolonged mechanical ventilation increase risk of fungal and viral reactivations.
• Antifungal immune responses may exacerbate lung injury via neutrophil-mediated inflammation.

Patient & Prescribing Data

ICU patients with severe viral pneumonia and nonresolving ARDS, including those with influenza or COVID-19

Antifungal therapy may improve outcomes in IAPA and CAPA; antiviral treatment benefits for HSV and CMV reactivation remain uncertain and lack robust trial data.

Clinical Best Practices

• Employ bronchoalveolar lavage sampling for accurate diagnosis of fungal and viral pulmonary infections in ARDS.
• Initiate mold-active azole antifungal therapy promptly upon diagnosis of invasive pulmonary aspergillosis.
• Interpret viral DNA detection cautiously, considering potential colonization versus active infection.
• Recognize the interplay between viral and fungal infections contributing to immune dysregulation and lung injury.
• Address knowledge gaps by standardizing diagnostic criteria and conducting randomized trials for antiviral treatments.

Related Resources & Content

• European Respiratory Review - Narrative Review on Viral and Fungal Infections in ARDS